

Review Form 1.6

Journal Name:	Asian Journal of Medicine and Health
Manuscript Number:	Ms_AJMAH_92168
Title of the Manuscript:	A Comparison of Efficacy of Two Brands of Enoxaparin In COVID-19 Patients: A Pilot Study
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajmah.com/index.php/AJMAH/editorial-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Abstract</p> <ul style="list-style-type: none"> - Please write full form of DVT and VTE. - Please rewrite this entire paragraph and improve the motivation of the work: "Enoxaparin, a complex, biologically derived low-molecular-weight heparin, is approved for a range of clinical indications associated with thromboembolic events such as DVT and VTE. Recently it is used in treating thromboembolic activities in COVID-19 patient has caught up a lot of attention. Recently, many brands have come up in the market for the same. In the Hospital, the ongoing brand of Enoxaparin 0.6 i.e., Clexane (Sanofi) falls short as well as in the pharmaceutical market." - Please mention which hospital - Please mention why this study is important, this is very important. The motivation of the work is very weak - Please mention what improvements were seen in the CBC profile for LMWX - Please remove comparison from keyword <p>Introduction</p> <ul style="list-style-type: none"> - I like the introduction, it is well presented with facts, but few updates with recent works are necessary to make it more interesting for wider audience - In the first paragraph, please cite the article (https://www.mdpi.com/2673-8112/2/7/64/htm) to add that mortality risk of Covid-19 patients with OSA is higher. - In the second paragraph, please cite these articles for diagnosing Covid patients and predicting mortality risks from haematology profiles <ul style="list-style-type: none"> a) https://arxiv.org/abs/2109.07846 b) https://ieeexplore.ieee.org/abstract/document/9689824 - Add few lines how misinformation spread fake covid treatments, please cite the following as recommended by WHO Infodemic Issue#10 https://www.mdpi.com/2227-9032/9/2/156 <p>Results:</p> <ul style="list-style-type: none"> - I appreciate this statement from the authors: "we cannot confirm that which brand of Enoxaparin is better in terms of efficacy" - In the figure 1 & 2, please include the units in the y-axis <p>Conclusion:</p> <ul style="list-style-type: none"> - Please rewrite the conclusion again. The work is very interesting, but lack of information will make it less interesting to the audience. - Please add the significant outcome of the study (through CBC). Mention which parameter improvement, study time to indicate how much treatment time might be required etc. 	
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Abdullah Bin Shams
Department, University & Country	University of Toronto, Canada